Share ownership Zai Lab Limited

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-02 EDT			5-day change	1st Jan Change
24.33 ^USD	-4.59%		-2.60%	+37.93%

09-24	Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading	MT
09-04	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading	MT

Share class: Zai Lab Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,132,222,310	1,064,820,568 ( 94.05 %)	9,776,920 ( 0.8635 %)	94.05 %

Major shareholders: Zai Lab Limited

Name	Stocks	%	Valuation
RTW Investments LP 9.032 %	10,276,998	9.032 %	262 M $
RTW Investments LP 5.778 %	6,574,032	5.778 %	167 M $
TCG Crossover Management LLC 5.394 %	6,137,627	5.394 %	156 M $
TCG Crossover Management LLC 5.394 %	6,137,627	5.394 %	156 M $
RA Capital Management LP 5.048 %	5,743,533	5.048 %	146 M $
RA Capital Management LP 4.151 %	4,723,533	4.151 %	120 M $
Adar1 Capital Management LLC 2.961 %	3,369,034	2.961 %	86 M $
Fidelity Management & Research Co. LLC 2.474 %	2,815,214	2.474 %	72 M $
Goldman Sachs & Co. LLC 2.035 %	2,315,480	2.035 %	59 M $
Woodline Partners LP 1.94 %	2,207,293	1.94 %	56 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Goldman Sachs & Co. LLC (Private Banking) 4.359 %	49,596,030	4.359 %	125 M $
Qiming Venture Partners Ltd. 4.296 %	48,883,643	4.296 %	123 M $
Wellington Management Co. LLP 4.228 %	48,112,590	4.228 %	122 M $
Jupiter Topco LLC 3.472 %	39,501,040	3.472 %	100 M $
Ying Du 1.715 %	19,508,280	1.715 %	49 M $
Fidelity Management & Research Co. LLC 1.668 %	18,975,019	1.668 %	48 M $
Yinhua Fund Management Co., Ltd. 1.446 %	16,448,900	1.446 %	42 M $
Fidelity Management & Research (Hong Kong) Ltd. 1.356 %	15,426,892	1.356 %	39 M $
ICBC UBS Asset Management Co. Ltd. 1.142 %	12,996,800	1.142 %	33 M $
Goldman Sachs International (Invt Mgmt) 1.075 %	12,232,369	1.075 %	31 M $
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	54.11%
Others	2.79%
State Street Corp.	0.11%
Unknown	42.99%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	54.65%
United Kingdom	0.66%
Sweden	0.45%
Denmark	0.45%
Hong Kong	0.31%
France	0.22%
Netherlands	0.11%
Luxembourg	0.06%
Ireland	0.03%
Switzerland	0.03%
Cayman Islands	0.02%
Austria	0.01%
China	0.01%

Based on 1000 largest holdings

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

Employees

1,784

Sector

Pharmaceuticals

More about the company